BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022 Pharmaceutical Investing
Gilead Announces First Global Regulatory Approval of Sunlenca® , the Only Twice-Yearly HIV Treatment Option Pharmaceutical Investing
Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans Pharmaceutical Investing
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care Pharmaceutical Investing
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio Pharmaceutical Investing
Love Pharma Announces Strategic Acquisition of Doc Hygiene Pharmaceuticals Inc. Pharmaceutical Investing
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review Life Science Investing
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics Pharmaceutical Investing
Merck and Orna Therapeutics Collaborate to Advance Orna's Next Generation of RNA Technology Life Science Investing
